BMY Bristol-Myers Squibb Company Stock Quote

publish chart | save to portfolio | create alert

Settings

BMY [NYSE]

Bristol-Myers Squibb Company

Healthcare | Drug Manufacturers - General | USA

statements

Index	S&P 500	P/E	-	EPS (ttm)	-0.11	Insider Own	0.10%	Shs Outstand	2.26B	Perf Week	1.55%
Market Cap	142.00B	Forward P/E	8.46	EPS next Y	7.46	Insider Trans	-10.57%	Shs Float	2.23B	Perf Month	9.16%
Income	-44.00M	PEG	-	EPS next Q	1.41	Inst Own	75.80%	Short Float	0.72%	Perf Quarter	1.09%
Sales	39.40B	P/S	3.60	EPS this Y	-33.90%	Inst Trans	-0.11%	Short Ratio	1.52	Perf Half Y	4.58%
Book/sh	22.22	P/B	2.84	EPS next Y	16.78%	ROA	0.00%	Target Price	74.06	Perf Year	9.46%
Cash/sh	9.39	P/C	6.71	EPS next 5Y	21.35%	ROE	-0.10%	52W Range	45.76 - 68.34	Perf YTD	-1.78%
Dividend	1.80	P/FCF	17.80	EPS past 5Y	10.90%	ROI	5.50%	52W High	-7.74%	Beta	0.65
Dividend %	2.85%	Quick Ratio	1.60	Sales past 5Y	10.50%	Gross Margin	71.50%	52W Low	37.78%	ATR	1.44
Employees	30000	Current Ratio	1.70	Sales Q/Q	75.50%	Oper. Margin	8.70%	RSI (14)	54.24	Volatility	1.81% 2.32%
Optionable	Yes	Debt/Eq	0.90	EPS Q/Q	-1.30%	Profit Margin	-0.10%	Rel Volume	0.39	Prev Close	62.84
Shortable	Yes	LT Debt/Eq	0.82	Earnings	Nov 05 BMO	Payout	-	Avg Volume	10.60M	Price	63.05
Recom	1.90	SMA20	0.80%	SMA50	3.49%	SMA200	5.34%	Volume	4,176,597	Change	0.33%

Nov-16-20

Upgrade

Societe Generale

Hold → Buy

$76

Nov-10-20

Resumed

Bernstein

Mkt Perform

Nov-06-20

Downgrade

Gabelli & Co

Buy → Hold

Oct-19-20

Upgrade

Guggenheim

Neutral → Buy

$70

Sep-29-20

Initiated

Berenberg

Buy

$73

Jul-28-20

Initiated

Raymond James

Outperform

$75

Apr-02-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$64

Mar-23-20

Downgrade

Societe Generale

Buy → Hold

$50

Feb-27-20

Initiated

Barclays

Equal Weight

$69

Jan-06-20

Resumed

Citigroup

Buy

$73

Dec-13-19

Upgrade

Argus

Hold → Buy

$80

Nov-22-19

Resumed

Morgan Stanley

Equal-Weight

$60

Oct-17-19

Resumed

BofA/Merrill

Buy

$60

Aug-14-19

Upgrade

Atlantic Equities

Neutral → Overweight

$63

May-28-19

Initiated

Goldman

Buy

May-20-19

Downgrade

Argus

Buy → Hold

May-03-19

Upgrade

Barclays

Equal Weight → Overweight

$53 → $55

May-03-19

Resumed

JP Morgan

Overweight

$62

Jan-15-19

Upgrade

Societe Generale

Sell → Buy

Oct-22-18

Downgrade

Citigroup

Buy → Neutral

Nov-25-20 01:14PM	Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer Zacks
Nov-24-20 02:54PM	Do Hedge Funds Love Bristol Myers Squibb Company (BMY) As Much As Buffett Does? Insider Monkey
06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Business Wire
06:15AM	Is Bristol Myers Squibb Stock a Buy? Motley Fool
Nov-23-20 11:33AM	Is Bristol-Myers Squibb (BMY) a Smart Long-term Buy? Insider Monkey
10:33AM	Schrödinger Climbs on $2.7 Billion Bristol-Myers Squibb Deal TheStreet.com
07:01AM	Schrödinger in drug development agreement with Bristol Myers worth up to $2.7 billion in milestone and royalty payments MarketWatch
06:30AM	Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb Business Wire
Nov-19-20 04:36PM	Jim Simons' Firm's Top 5 Sells of the 3rd Quarter GuruFocus.com
Nov-18-20 12:24PM	Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS Zacks
06:08AM	Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks Motley Fool
01:29AM	15 Largest Biotech Companies in the World Insider Monkey
Nov-17-20 03:39PM	Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia Motley Fool
12:43PM	Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed Zacks
11:12AM	Why Did Warren Buffetts Berkshire Hathaway Fall Out of Love With JPMorgan? Barrons.com
09:45AM	Should Value Investors Now Choose Bristol Myers (BMY) Stock? Zacks
08:30AM	Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Companys Leading Cardiovascular Franchise Business Wire
06:59AM	The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials Business Wire
01:42AM	Stocks Retrace, Tesla Makes S&P 500, Retail Sales, OPEC+ - What's up in Markets Investing.com
Nov-16-20 07:56PM	Warren Buffett Likes Stocks Again Bloomberg
06:54PM	Warren Buffett Bought 4 Pharma Giants in Q3 Motley Fool
05:34PM	FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs Reuters
05:30PM	Warren Buffett's Berkshire Hathaway reports new stakes in AbbVie, Pfizer, Merck, Bristol-Myers Squibb Yahoo Finance Video
04:38PM	Bristol Myers CVR Dealt Blow as Key Drug Faces Approval Hurdle Bloomberg
04:30PM	Warren Buffett's Berkshire loads up on Pfizer, other pharma stocks in Q3; exits Costco Yahoo Finance
04:21PM	Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel) Business Wire
01:54PM	15 Largest Drug Companies in the World Insider Monkey
Nov-13-20 03:22PM	Is Pfizer Stock A Buy After Its Coronavirus Vaccine Proved 90% Effective? Investor's Business Daily
Nov-12-20 07:15AM	Bristol Myers Announced Another Major Acquisition But Is BMY Stock A Buy? Investor's Business Daily
Nov-11-20 04:15PM	Bristol Myers Squibb to Participate in Wolfe Researchs 2nd Annual Virtual Healthcare Conference Business Wire
06:59AM	Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020 Business Wire
Nov-10-20 12:35PM	5 Leading Healthcare Stocks Surging On Pent-Up Demand Insider Monkey
Nov-09-20 07:27PM	Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes Business Wire
05:05PM	Kahn Brothers' Biggest 3rd-Quarter Sells GuruFocus.com
11:29AM	Kahn Brothers Cuts Merck & Co., Bristol-Myers GuruFocus.com
10:03AM	Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative Moody's
06:59AM	Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis Business Wire
Nov-08-20 07:24AM	Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year Simply Wall St.
Nov-06-20 08:15PM	No Stimulus? This Expansion Still Looks Self-Sustaining, Says One Economist Barrons.com
11:20AM	Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss Zacks
10:33AM	Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat Zacks
06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Business Wire
02:31AM	Bristol-Myers Squibb (BMY) Q3 2020 Earnings Call Transcript Motley Fool
01:31AM	Acceleron Pharma Inc (XLRN) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:08PM	Why The No. 1 Pharma Stock Stumbled Despite Its Third-Quarter Beat Investor's Business Daily
02:00PM	How Bristol Myers Squibb Beat Wall Street Estimates in Q3 Motley Fool
11:17AM	Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised Zacks
10:41AM	What Does Bristol-Myers Squibb's Debt Look Like? Benzinga
10:41AM	All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag Bloomberg
10:00AM	Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 6.8% Zacks
09:43AM	Bristol-Myers Beats Q3 Earnings Forecast, Lifts 2020 Outlook As Celgene Boosts Revenues TheStreet.com
08:25AM	Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates Zacks
08:22AM	Recap: Bristol-Myers Squibb Q3 Earnings Benzinga
07:25AM	Bristol Myers Squibb's stock gains with Eliquis sales jumping 9% during the third quarter MarketWatch
07:01AM	Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases Business Wire
06:59AM	Bristol Myers Squibb Reports Third Quarter 2020 Financial Results Business Wire
06:59AM	Better-than-expected sales drive Bristol Myers earnings Reuters
Nov-04-20 08:32AM	Why Earnings Season Could Be Great for Bristol-Myers Squibb (BMY) Zacks +6.84%
06:59AM	Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period Business Wire
06:01AM	Here's What's Behind Bristol Myers Squibb's Huge Acquisitions Motley Fool
Nov-03-20 04:14PM	Bristol Myers Squibb Says Its Drug Outperforms Drug It Sold To Amgen Investor's Business Daily
02:03PM	Bristol Myers Squibb Reports Success in Pivotal Trial of Psoriasis Drug Motley Fool
10:48AM	Bristol Myers Says Its Psoriasis Drug Outperformed Amgens Otezla Barrons.com
09:46AM	Bristol-Myers Shares Leap After Positive Data From Late-Stage Psoriasis Drug Trial TheStreet.com
07:38AM	The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga
06:59AM	Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study Business Wire
06:59AM	Bristol Myers psoriasis drug succeeds in late-stage study Reuters
Nov-02-20 11:58AM	Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day Zacks
05:50AM	Uber, T-Mobile, Peloton, Regeneron and Other Stocks to Watch This Week Barrons.com
Nov-01-20 02:33AM	Economic Calendar - Top 5 Things to Watch This Week Investing.com
Oct-31-20 08:22AM	Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks? Motley Fool
Oct-30-20 10:49AM	Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings? Zacks
Oct-29-20 02:12PM	The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley Zacks
12:35PM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:14AM	3 Dividend Stocks to Buy on Sale Motley Fool
06:05AM	Thank Otezla for Amgen's Q3 Revenue and Earnings Beats Motley Fool
Oct-28-20 04:48PM	Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund GuruFocus.com
12:47PM	Top Analyst Reports for Thermo Fisher, SAP & Bristol-Myers Zacks
12:30PM	Family Members of Christine Jessop Demand Independent Review of Murder Investigation CNW Group
Oct-27-20 08:45AM	3 Recession Proof Stocks to Buy Now Motley Fool
07:05AM	These 2 Pharmas Have Made Their Pipelines a Competitive Advantage Motley Fool
Oct-26-20 05:45PM	Bristol Myers Squibb (BMY) Stock Moves -0.77%: What You Should Know Zacks
02:47PM	Best Dividend Stocks for November 2020 Investopedia
08:00AM	Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions1 Business Wire
05:51AM	Got $3,000? 4 Proven Stocks to Buy Right Now Motley Fool
Oct-24-20 07:30AM	2 Top Pharma Stocks to Buy Right Now Motley Fool
Oct-23-20 10:05AM	Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus Zacks
07:11AM	3 Bargain Stocks You Can Buy Right Now Motley Fool
Oct-22-20 10:15AM	Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus Zacks
Oct-21-20 10:48AM	Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II Zacks
Oct-19-20 05:25PM	Were Hedge Funds Right About Bristol Myers Squibb Company (BMY)? Insider Monkey
05:21PM	'Halftime Report' Traders Share Their Thoughts On Guggenheim's Bristol-Myers Call Benzinga
04:27PM	Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment Investor's Business Daily
03:24PM	Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk Benzinga
12:06PM	Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU Zacks
11:55AM	Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC Zacks
11:47AM	Bristol-Myers Lifted to Buy at Guggenheim on Opdivo Optimism TheStreet.com
09:50AM	Bristol Myers Stock Skeptic Upgrades to a Buy. Heres Why. Barrons.com
06:59AM	U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma Business Wire
06:06AM	4 Perfect Stocks to Buy if the Stock Market Crashes Motley Fool

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrodinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
von Autenried Paul	EVP, Chief Information Officer	Nov 24	Sale	62.75	20,000	1,255,000	126,701	Nov 25 04:31 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Nov 24	Sale	63.39	900	57,051	15,186	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 23	Sale	61.34	13,421	823,244	37,922	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Option Exercise	49.28	52,213	2,572,887	98,355	Nov 23 05:40 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Sale	61.30	57,591	3,530,269	46,142	Nov 23 05:40 PM
AHMED NADIM	EVP and President, Hematology	Oct 30	Option Exercise	0.00	4,650	0	30,680	Nov 03 04:28 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Oct 30	Option Exercise	0.00	5,804	0	59,580	Nov 03 04:27 PM
Santiago Karen Murphy	SVP & Controller	Sep 01	Option Exercise	0.00	642	0	8,390	Sep 02 04:33 PM
Caforio Giovanni	Chairman and CEO	Aug 31	Sale	62.70	39,840	2,497,968	445,584	Sep 02 04:34 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Aug 17	Sale	64.00	5,327	340,928	2,534	Aug 19 06:15 PM
LEUNG SANDRA	EVP, General Counsel	Aug 13	Sale	63.24	141,420	8,943,401	432,744	Aug 17 04:55 PM
Elkins David V	EVP, Chief Financial Officer	Aug 01	Option Exercise	0.00	46,402	0	80,698	Aug 04 04:43 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Jul 01	Option Exercise	0.00	9,356	0	9,356	Jul 02 04:56 PM
Santiago Karen Murphy	SVP & Controller	Jul 01	Option Exercise	0.00	1,069	0	8,115	Jul 02 04:54 PM
Paliwal Dinesh C	Director	Jun 15	Buy	54.50	9,174	499,983	22,109	Jun 16 05:15 PM
Haller Julia A	Director	Jun 14	Option Exercise	0.00	558	0	6,819	Jun 16 05:15 PM
BONNEY MICHAEL W	Director	Jun 14	Option Exercise	0.00	558	0	8,650	Jun 16 05:16 PM
Haller Julia A	Director	Jun 13	Option Exercise	0.00	903	0	6,261	Jun 16 05:15 PM
BONNEY MICHAEL W	Director	Jun 13	Option Exercise	0.00	903	0	8,092	Jun 16 05:16 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Jun 03	Option Exercise	0.00	2,154	0	8,599	Jun 09 07:15 PM
Haller Julia A	Director	Jun 03	Option Exercise	0.00	2,949	0	5,358	Jun 05 04:39 PM
BONNEY MICHAEL W	Director	Jun 03	Option Exercise	0.00	2,949	0	7,189	Jun 05 04:40 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	May 22	Sale	61.01	3,200	195,232	16,086	May 26 05:17 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	May 19	Sale	62.68	25,000	1,567,000	26,777	May 21 05:22 PM
VESSEY RUPERT	EVP, Research & Early Dev.	May 01	Option Exercise	0.00	10,707	0	59,050	May 05 04:49 PM
AHMED NADIM	EVP and President, Hematology	May 01	Option Exercise	0.00	2,908	0	27,463	May 05 04:49 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	Mar 10	Option Exercise	0.00	30,519	0	58,379	Mar 12 06:18 PM
von Autenried Paul	EVP, Chief Information Officer	Mar 10	Option Exercise	0.00	20,806	0	152,400	Mar 12 06:19 PM
Powell Ann	EVP, Chief Human Resources	Mar 10	Option Exercise	0.00	31,169	0	58,421	Mar 12 06:17 PM
Santiago Karen Murphy	Controller	Mar 10	Option Exercise	0.00	5,063	0	7,778	Mar 12 06:17 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10	Option Exercise	0.00	51,598	0	588,175	Mar 12 06:15 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Mar 10	Option Exercise	0.00	1,571	0	6,652	Mar 12 06:13 PM
Elicker John E	EVP, Investor Relations	Mar 10	Option Exercise	0.00	18,407	0	75,102	Mar 12 06:14 PM
Caforio Giovanni	Chairman and CEO	Mar 10	Option Exercise	0.00	211,796	0	544,032	Mar 12 06:11 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Mar 10	Option Exercise	0.00	5,007	0	20,091	Mar 12 06:12 PM
Bancroft Charles A	EVP, Head of Integration	Mar 10	Option Exercise	0.00	71,868	0	153,637	Mar 12 06:11 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 10	Option Exercise	0.00	21,426	0	26,091	Mar 12 06:11 PM
Elicker John E	EVP, Investor Relations	Mar 04	Sale	61.01	15,805	964,263	58,666	Mar 06 05:20 PM
VESSEY RUPERT	Pres., Research & Early Dev.	Mar 02	Option Exercise	51.69	93,468	4,831,452	132,651	Mar 04 06:19 PM
VESSEY RUPERT	Pres., Research & Early Dev.	Mar 02	Sale	60.59	84,308	5,108,222	48,343	Mar 04 06:19 PM
AHMED NADIM	President, Hematology	Mar 01	Option Exercise	0.00	17,204	0	33,028	Mar 03 08:04 PM
Elkins David V	EVP, Chief Financial Officer	Mar 01	Option Exercise	0.00	24,579	0	44,766	Mar 03 08:04 PM
VESSEY RUPERT	Pres., Research & Early Dev.	Mar 01	Option Exercise	0.00	23,349	0	48,106	Mar 03 08:05 PM
AHMED NADIM	President, Hematology	Feb 04	Option Exercise	0.00	2,076	0	16,895	Feb 06 08:48 PM
VESSEY RUPERT	Pres., Research & Early Dev.	Feb 04	Option Exercise	0.00	3,592	0	25,920	Feb 06 08:49 PM
Elkins David V	EVP, Chief Financial Officer	Dec 31	Option Exercise	0.00	12,373	0	26,281	Jan 03 07:00 PM
VESSEY RUPERT	Pres., Research & Early Dev.	Dec 31	Option Exercise	0.00	16,060	0	30,778	Jan 03 07:00 PM
Dubow Adam	Chief Compliance & Ethics Offi	Dec 05	Sale	58.81	1,740	102,329	15,749	Dec 09 04:44 PM
BONNEY MICHAEL W	Director	Dec 04	Buy	58.90	88	5,183	7,189	Jun 09 07:16 PM
Eid Joseph	SVPHead Global Medical Affairs	Dec 01	Option Exercise	0.00	2,825	0	4,995	Dec 03 05:28 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience